Colorectal Carcinoma Clinical Trial
Official title:
A Brief Online Mindfulness-Based Intervention to Decrease Pre-Procedural Anxiety Before a First-Time Screening Colonoscopy: A Pilot Randomized Controlled Trial
Verified date | January 2024 |
Source | Ohio State University Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial tests how well an online mindfulness-based intervention (MBI) works to decrease anxiety in patients before a first-time screening colonoscopy. Elevated pre-procedural anxiety can affect patient outcomes including bowel preparation adherence and quality, the amount of sedation required, procedure time, patient satisfaction, cancellation or no-shows, and intention for future cancer screening. Mindfulness is a form of meditation that focuses on staying within the present moment to reduce anxiety. Previous research supports mindfulness practice among cancer survivors to decrease anxiety, fear of cancer re-occurrence, and to improve quality of life. Online MBIs have the potential to include targeted meditations and educational information designed to promote behavior change. This study may help researchers learn whether a mindfulness intervention works to decrease anxiety in patients before a first-time screening colonoscopy.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 45 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients must be ages 45-75 - Patients must be at average risk for colorectal cancer (CRC) - Patients must have scheduled their first-time screening colonoscopy as an outpatient at Ohio State University (OSU) at least 14 days in advance - Patients must be able to speak and read English - Patients must have daily access to a working telephone, email address, and internet connection - Patients must provide consent Exclusion Criteria: - Previous colonoscopy - Colonoscopy for diagnostic purposes - Auditory or visual impairment that prevents internet use - Previous cancer diagnosis (other than skin cancer) - Previous diagnosis of a mental health disorder - Current mental health treatment - Family history of CRC - Personal history of inflammatory bowel disease (ulcerative colitis or Crohn's disease) - Confirmed or suspected hereditary CRC syndrome, such as familial adenomatous polyposis or Lynch syndrome |
Country | Name | City | State |
---|---|---|---|
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University Comprehensive Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Retention rate (Feasibility) | Feasibility will be assessed by the number of patients referred, number of participants recruited, and missing data from surveys and medical records. Feasibility will be achieved with a retention rate of 90% throughout the intervention. An independent samples t-test will be conducted to compare State-Trait Anxiety Inventory: State-Subscale (STAI-S) scores. Linear regression will be conducted to assess the difference when controlling for potential confounding variables of interest. | Up to 4 weeks | |
Primary | Satisfaction with the intervention (Acceptability) | Acceptability will be assessed by the number of intervention materials accessed and time to complete study activities (infographics, meditations, and surveys) via embedded REDCap metrics. Participants within the MBI group will also report meditation satisfaction and state mindfulness immediately after each meditation in addition to intervention satisfaction during the follow-up survey. Will report an average satisfaction score with the intervention >= 6.0, measured using a 7-point Likert scale. An independent samples t-test will be conducted to compare STAI-S scores. Linear regression will be conducted to assess the difference when controlling for potential confounding variables of interest. | At follow-up (1-2 days after the colonoscopy) | |
Secondary | Colonoscopy nervousness | Anxiety specific to the bowel prep and colonoscopy will be assessed using a visual analogue scale. Will be analyzed using t-test. | At pre-colonoscopy assessment | |
Secondary | Mindfulness | Will measure the trait mindfulness using The Philadelphia Mindfulness Scale, a 20-item self-report with subscales of awareness and acceptance. Will be analyzed using t-test. | At follow-up (1-2 days after the colonoscopy) | |
Secondary | Mindfulness knowledge | Will be assessed using a 5-item score about mindfulness. An independent samples t-test will be conducted to compare STAI-S scores. | At follow up (1-2 days after the colonoscopy) | |
Secondary | Colorectal screening knowledge | Will be assessed using a 5-item score about colorectal (CRC) screening. Will be analyzed using t-test. | At follow up (1-2 days after the colonoscopy) | |
Secondary | Attitudes about CRC and CRC screening | Will be self-reported and measured on a 5-point Likert scale. Will be analyzed using t-test. | At follow up (1-2 days after the colonoscopy) | |
Secondary | Bowel prep adherence | Will be self-reported and measured on a 5-point Likert scale. Will be analyzed using chi-square test. | At pre-colonoscopy assessment | |
Secondary | Bowel prep difficulty | Will be self-reported and measured on a 5-point Likert scale. Will be analyzed using t-test. | At pre-colonoscopy assessment | |
Secondary | Bowel prep quality | Will be measured using the Boston Bowel Preparation Scale or 5-point Likert scale and medical chart review. Will be analyzed using t-test. | Up to 4 weeks | |
Secondary | Cancellation/no-show | Will be measured by attendance. Will be analyzed using chi-square test. | At pre-colonoscopy assessment | |
Secondary | Heart rate | Will be measured in beats per minute using medical chart review. Will be analyzed using t-test. | Up to 4 weeks | |
Secondary | Blood pressure | Will be measured in millimeter of mercury using chart review at time of check-in (the first recorded) to the endoscopy suite holding area. Will be analyzed using t-test. | Up to 4 weeks | |
Secondary | Sedative dose | Will be measured in milligrams using chart review. Will be analyzed using t-test. | Up to 4 weeks | |
Secondary | Procedural time | Will be measured in minutes using medical chart review. Will be analyzed using t-test. | Up to 4 weeks | |
Secondary | Cecal intubation time | Will be measured in minutes using medical chart review. Will be analyzed using t-test. | At post-colonoscopy | |
Secondary | Endoscopy suite time | Will be measured in minutes using medical chart review. Will be analyzed using t-test. | Up to 4 weeks | |
Secondary | Procedure satisfaction | Will be self-reported and measured on a 5-point Likert scale. Will be analyzed using t-test. | At follow up (1-2 days after the colonoscopy) | |
Secondary | Intent for future CRC screening | Will be self-reported and measured on a 5-point Likert scale. Will be analyzed using t-test. | At follow up (1-2 days after the colonoscopy) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04444232 -
Cancer Communication Within Hispanic Social Networks
|
N/A | |
Recruiting |
NCT05799820 -
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
|
Phase 2 | |
Recruiting |
NCT04666727 -
Role of Diet on the Microbiome of the Digestive System
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT02376452 -
Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
|
Phase 2 | |
Completed |
NCT02254486 -
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults
|
Phase 3 | |
Completed |
NCT01486251 -
Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer
|
N/A | |
Terminated |
NCT01233544 -
Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases
|
Phase 3 | |
Recruiting |
NCT02073500 -
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
|
||
Completed |
NCT00704600 -
Nelfinavir, a Phase I/Phase II Rectal Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00485316 -
Laparoscopic Assisted Versus Open Resection for Colorectal Carcinoma
|
Phase 3 | |
Recruiting |
NCT04430738 -
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
|
Phase 1/Phase 2 | |
Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
Completed |
NCT05022511 -
Three Birds With One Stone
|
N/A | |
Completed |
NCT04607291 -
Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening
|
Phase 1 | |
Not yet recruiting |
NCT03969784 -
Microparticles in Peritoneal Carcinomatosis of Colorectal Origin
|
N/A | |
Not yet recruiting |
NCT05630794 -
Testing ONC201 to Prevent Colorectal Cancer
|
Phase 1 | |
Terminated |
NCT05291988 -
A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial
|
N/A | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03142516 -
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
|
Phase 2 |